Letter to the Editor: Response to Fitzgerald T et al. Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA.

Blauvelt, Andrew; Garrelts, Alyssa; Malatestinic, William; Birt, Julie; Zhu, Baojin; Feely, Meghan

Blauvelt, Andrew; Garrelts, Alyssa; Malatestinic, William; Birt, Julie; Zhu, Baojin; Feely, Meghan.

Afiliación

Blauvelt A; Oregon Medical Research Center, Portland, OR, USA. ablauvelt@oregonmedicalresearch.com.
Garrelts A; Eli Lilly and Company, Indianapolis, IN, USA.
Malatestinic W; Eli Lilly and Company, Indianapolis, IN, USA.
Birt J; Eli Lilly and Company, Indianapolis, IN, USA.
Zhu B; Eli Lilly and Company, Indianapolis, IN, USA.
Feely M; Eli Lilly and Company, Indianapolis, IN, USA.

Dermatol Ther (Heidelb) ; 13(11): 2911-2916, 2023 Nov.

Article en En | MEDLINE | ID: mdl-37752409

Palabras clave

Claims data; Clinical interpretation; Methodology; Persistence; Psoriasis

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Dermatol Ther (Heidelb) Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Suiza

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google